Wanpu Yan
Peking University(CN)Peking University Cancer Hospital(CN)Ministry of Education(ET)
Publications by Year
Research Areas
Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes, Esophageal and GI Pathology
Most-Cited Works
- → Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study(2019)262 cited
- → Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma(2017)80 cited
- → Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial(2023)74 cited
- → Efficacy of transcutaneous electrical acupoint stimulation combined with general anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: A randomized, double‐blind, placebo‐controlled trial(2020)60 cited
- → HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair(2019)53 cited
- → The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma